Marc Gitzinger's path with BioVersys didn't begin on the trading floor—it began in the Swiss startup trenches. As a student at ETH Zurich, he joined the Venture Challenge semester course in 2007 to le...

http://reut.rs/4jBW45G

Antibiotika-Resistenzen sind ein immer grösseres Problem. Sie erschweren die Behandlung vieler Infektionen, führen zu längeren oder auch schwereren Krankheitsverläufen. Laut Weltgesundheitsorganisatio...

Das Basler Biotechunternehmen Bioversys hat am Freitag den ersten Börsengang des Jahres in der Schweiz gemacht. Bei einem Kurs von 36,50 Franken ist die Aktie in den Handel an der Schweizer Börse SIX ...

BASEL, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out...

Bacteria use two-component regulatory systems (TCSs) to adapt to changes in their environment by changing their gene expression. In this study, we show that the EnvZ/OmpR TCS of the clinically relevan...

BioVersys vient de signer un accord à plus de 470 millions avec le laboratoire japonais Shionogi pour accélérer le développement de traitements contre les infections provoquées par des bactéries résis...

Lung & Respiratory Breakthroughs: ALYFTREK Approval, IPF Trial Milestones, PAH Advancements and more   This week on Lung and Respiratory […] The post Respiratory Weekly News – July 4th 2025 appeared first on LucidQuest Ventures.

BioVersys AG (BIOV), a biotech company specializing in antimicrobial resistance solutions, has successfully raised total gross proceeds of CHF76.7 million

BioVersys Secures Key Patent in China for BV100 Drug  TipRanks

BioVersys, a Switzerland-based multi-asset, clinical stage biopharmaceutical company focusing on R&D of novel antibacterial products, has priced its IPO at CHF36 per share, implying a market cap of CHF213m (US$235m).This is the first IPO on SIX Swiss in 2025 and the first biotech IPO in Switzerland since 2018.Some 2,222,221 shares were placed in the all-primary offer, including the 138.888 over-allotment option, to raise CHF80m.GlaxoSmithKline and AMR Action Fund have committed to invest CHF3.5m and CHF16m respectively.Shares began trading today (February 7) on SIX Swiss. Shares were last quoted at CHF26Citi, UBS and Stifel were joint global coordinators. Octavian and Mirabaud

Lung & Respiratory Breakthroughs: ALYFTREK Approval, IPF Trial Milestones, PAH Advancements and more   This week on Lung and Respiratory […] The post Respiratory Weekly News – July 4th 2025 appeared first on LucidQuest Ventures.

Die Schweizer Bioversys strebt an die SIX Swiss Exchange. Die Erlöse aus dem IPO will das auf Arznei gegen multiresistente Bakterien spezialisierte Biotechunternehmen für die Weiterentwicklung des führenden Produkts bis zur Zulassung einsetzen.

Explore the robust advancements in tuberculosis treatments as over 30 pharmaceutical companies participate in the clinical trial pipeline for TB therapies. Discover recent developments and key players shaping the future of TB treatment.

http://reut.rs/3E5faRp